Revolutionizing the traditional
fertility process through
innovative therapeutics

Cell engineering is curing diseases from cancer to heart disease. We believe novel advances in the field can improve and modernize the entire female reproductive journey.

We are here to make a change.

Ovarian decline affects women throughout their lifetime, causing disease of the female reproductive system, infertility, and menopause. Most of these conditions have few treatment options, and those that do exist cause complications and don’t cure the underlying disease.

At the core of our work is cell engineering. We are using it to modernize and destigmatize the traditional fertility process.

US Headquarters:
New York, NY
European Headquarters:
Madrid, Spain

We bring together scientists, innovators, and experts passionate about modernizing and improving women's health

Management Team

Board of Directors

Dina Radenkovic

Dina is a medical doctor and a healthcare entrepreneur. Prior to her role as Co-founder & CEO of Gameto, Dr Dina Radenkovic was a partner at SALT Bio Fund (salt.org) and had research posts at King’s College London and the Buck Institute for Research on Aging. Dina was also co-founder & Chief Science Officer of Hooke, a longevity research clinic in London. She qualified with a dual degree in medicine and physiology from UCL Medical School awarded the best overall performance in physiology BSc. Dina did her residency at St Thomas’ Hospital in London. She has over 30 academic papers, 7 grants and over 40 scientific conference presentations. She is fluent in 5 languages and 3 programming languages.

Dina Radenkovic
Co-founder & Chief Executive Officer

Teri Loxam

Prior to joining Gameto, Teri was Chief Operating Officer & Chief Financial Officer at Kira Pharmaceuticals, a clinical-stage biotech company developing transformative therapies for people with complement-mediated diseases. There, she helped build out the strategy, operations and financial functions across the U.S. and China locations to get the company public-ready. Before Kira, Teri served as Chief Financial Officer of SQZ Biotechnologies, a novel cell therapy company developing treatments for cancer, infectious disease and other serious conditions. While at SQZ she was instrumental in raising more than $200M, including taking the company public in October 2020. Prior to joining SQZ, Teri held various positions at Merck, IMAX Corporation, and Bristol-Myers Squibb across communications, strategy, treasury, and investor relations. Teri is a member of the board of directors and audit chair of Vaxcyte, Inc. and Cardiol Therapeutics, Inc. She has a B.S. in Biology from the University of Victoria, B.C. Canada and an MBA from the University of California, Irvine.

Teri Loxam
Chief Financial Officer

Christian Kramme

Prior to joining Gameto as the VP of Cellular Engineering, Christian Kramme completed his PhD at Harvard Medical School working with the Sponsored Research Agreement of Gameto and Professor George Church’s lab. His thesis work “Multimodal investigation of human in vitro oogenesis” was based on high-throughput screening of transcription factors for generation of human germ cells, oocytes, and ovarian supporting cells to model genetic causes of infertility. Prior to Harvard, Christian received his B.S. in Molecular Genetics from UCLA, graduating Magna Cum Laude. While at UCLA, Christian conducted research on cannabinoids for migraine and chronic pain treatment. His work on synthetic biology and cell engineering for human oogenesis has yielded numerous patents and publications.

Christian Kramme
Vice President of Cellular Engineering

Agustina Imfeld

Agustina graduated with a Bachelor of Laws from the Universidad Nacional del Nordeste in Corrientes where she completed the six-year law degree in fewer than three. She also completed an MBA in Innovation Management at the Universidad de Buenos Aires, and graduated from the University of Georgia Master of Laws program where she received a merit-based full scholarship. Her most recent role was in Complex Litigation at Clarin Group, where she worked on high-stakes cases, such as securing an injunction against the federal government of Argentina to suspend the nationalization of telecommunication services. Agustina has performed pro bono work, including a project funded by the United Nations Democracy Fund which aims to promote vulnerable women’s access to justice in civil cases. She was selected as one of 500 young leaders in LATAM by the Climate Finance Group for Latin America and the Caribbean to promote transparency and accountability of international financing in climate change.

Agustina Imfeld
Counsel

Milos Fulton

An MBA from IE Business School, Milos Fulton has been with Gameto since incorporation. Milos is a finance generalist with extensive startup experience. He started his career at Jazzya Investments, managing early-stage technology investments and at Fon as a business development representative. He later worked at PAL Capital, providing M&A advisory to international startups, Feedback Loop as an early employee holding a variety of roles, and PlaceAVote as part of the founding team. After his MBA, Milos rejoined Jazzya Investments as VP of Finance. While at Jazzya, Milos worked as the consulting VP of Finance with portfolio company Overture Life, a company working to automate the embryology lab. Milos has since remained in the fertility industry, transitioning from Jazzya to Gameto.

Milos Fulton
Vice President of Business Operations

Sabrina Piechota

Sabrina leads the embryology department at Gameto, instrumental to the validation of Fertilo. Prior to joining Gameto, Sabrina worked at women’s health startup Aspira Women’s Health, where she was instrumental in building out Aspira’s state of the art molecular science laboratory. Prior to working for Aspira, Sabrina worked for four years as a clinical embryologist at the Reproductive Medicines Associates of Connecticut, where she became skilled in egg retrievals, denudation of oocytes, assisted laser hatching, complex sperm preparation, embryo thaw & vitrification, frozen/fresh embryo transfer, conventional insemination, and intracellular sperm injection. Sabrina holds a Bachelor of Science in Biology from the University of Hartford and a CLIA state certification, and with both clinical and medical backgrounds brings diverse expertise to the team at Gameto.

Sabrina Piechota
Embryology Department Manager

Emily Bosworth

Emily leads the business development team at Gameto. Having joined the company as an early employee in a generalist role, Emily has since honed her focus on business development and strategy, utilizing her expertise to drive growth and success for the company. Emily's prior experience includes healthcare consulting at ClearView Healthcare Partners, where she advised clients ranging from biotech start-ups to large pharmaceutical companies across various therapeutic areas. In particular, she developed key commercialization and value, pricing, and access strategies. Emily holds a bachelor's degree from Harvard College, having graduated Magna Cum Laude in Neuroscience and Global Health & Health Policy, and brings a deep understanding of the healthcare landscape to her work at Gameto.

Emily Bosworth
Business Development Manager

Bruna Paulsen

Bruna is a stem cell biologist, with over 15 years of expertise in reprogramming, human pluripotent stem cell culture and differentiation approaches to generate disease-relevant cell types, and identify disorder-specific phenotypes in vitro. Prior to joining Gameto, Bruna Paulsen did her postdoctoral research at the Department of Stem Cell and Regenerative Biology at Harvard University. Bruna has a successful publication record with 23 peer-reviewed and 7 as first-author publications including Nature and Nature Biomedical Engineering, and over 30 invited presentations and multiple awards, including International Society for Stem Cell Research Award for Scientific Excellence, and Rising Star Award from Massachusetts Institute of Technology.

Bruna Paulsen
Manufacturing Manager
Dina Radenkovic

Dina Radenkovic

Dina is a medical doctor and a healthcare entrepreneur. Prior to her role as Co-founder & CEO of Gameto, Dr Dina Radenkovic was a partner at SALT Bio Fund (salt.org) and had research posts at King’s College London and the Buck Institute for Research on Aging. Dina was also co-founder & Chief Science Officer of Hooke, a longevity research clinic in London. She qualified with a dual degree in medicine and physiology from UCL Medical School awarded the best overall performance in physiology BSc. Dina did her residency at St Thomas’ Hospital in London. She has over 30 academic papers, 7 grants and over 40 scientific conference presentations. She is fluent in 5 languages and 3 programming languages.

Dina Radenkovic
CEO and Director
Martin Varsavsky

Martin Varsavsky

Martin Varsavsky is a serial entrepreneur, professor, and investor. He has founded 8 companies in the last 30 years. He is co-founder of Overture Life, a company automating the embryology lab. Martin is the founder & non-executive chairman of Prelude Fertility, the largest network of fertility clinics in the United States. Previously, he founded several successful ventures in the technology space including Jazztel, Spain’s second-largest publicly traded telecom operator; Viatel, best known for inventing call-back and building the first pan-European fiber optic network, and Eolia Renovables. Martin is the recipient of various honors and rewards, among them European Telecommunications Entrepreneur of the Year in 1998, ECTA’s European Entrepreneur of the Year in 1999, Global Leader for Tomorrow by the World Economic Forum in Davos, 2000, and Spanish Entrepreneur of the Year in 2000, Pickering Prize from Columbia University 2004.

Martin Varsavsky
Chairman
Maryanna Saenko

Maryanna Saenko

Maryanna Saenko is an early-stage venture capitalist with an interest in robotics, quantum computing, blockchain, aerospace, and the future of food. Prior to co-founding Future Ventures, she was at Khosla Ventures, and prior to that at DFJ, where she worked with her co-founder Steve Jurvetson to focus on frontier technology investments. She was also an investment partner at Airbus Ventures where she led a series of venture investments strategically aligned with Airbus’ future-of-aerospace initiatives. Before Airbus, Maryanna was a consultant at Lux Research and a research engineer at Cabot Corporation. Maryanna graduated from Carnegie Mellon University with a BS in BioMedical Engineering and a BS and MS in Materials Science and Engineering. Maryana is now a co-founder at Future Ventures, a VC firm that has invested in biotech companies including Faeth Therapeutics, Deep Genomics, and Neuralink.

Maryanna Saenko
Director
Dylan Morris

Dylan Morris

Dylan Morris is a Managing Director at Insight. He joined the firm in 2021 to focus on investments in computational biology. Dylan was previously a general partner at CRV, where he built the bioengineering practice, leading the firm’s investments in Dyno Therapeutics, Recursion Pharmaceuticals, and Plexium, among others. Prior to CRV, Dylan invested at Innovation Endeavors, Eric Schmidt’s early-stage venture capital firm, where he drove investments in companies operating at the intersection of data science and life science. Before becoming an investor, Dylan co-founded Integrated Plasmonics, a venture-backed point-of-care diagnostics startup. Prior to that, he conducted graduate research in biochemistry and molecular biophysics at Caltech, where he co-authored multiple peer-reviewed publications. Dylan received his A.B. in Computer Science from Harvard University.

Dylan Morris
Director

Scientific Advisory Board

Professor George Church

Professor George Church

George Church is a Professor of Genetics at Harvard Medical School and Professor of Health Sciences and Technology at Harvard and MIT. He leads Synthetic Biology at Harvard’s Wyss Institute, where he oversees the directed evolution of molecules, polymers, and whole genomes to create new tools with applications in regenerative medicine and bio-production of chemicals. Professor Church is widely recognized for his innovative contributions to genomic science and his many pioneering contributions to chemistry and biomedicine. In 1984, he developed the first direct genomic sequencing method, which resulted in the first genome sequence (the human pathogen, H. pylori). He later helped initiate the Human Genome Project in 1984 and the Personal Genome Project in 2005. Professor Church invented the broadly applied concepts of molecular multiplexing and tags, homologous recombination methods, and array DNA synthesizers. His innovations have been the basis for many companies including Editas (Gene therapy); Gen9bio (Synthetic DNA); and Veritas Genetics (full human genome sequencing).

Professor George Church
Professor Kristin Baldwin

Professor Kristin Baldwin

Kristin Baldwin is a Professor of Genetics and Development at Columbia University and member of the Columbia Stem Cell Initiative. She is a pioneer in reprogramming and stem cell biology. Her research applies reprogramming to assess the impact of aging on diverse cell types and to engineer new cellular models for neurologic, and cardiovascular disease. Dr. Baldwin's earlier notable work included being the first to clone a mouse from a neuron and then sequence its genome and producing an entire mouse from a skin cell with iPSCs. Her work has been published in premiere journals (i.e Nature, Cell) and has garnered awards (i.e. Pew Scholar, Kavli Fellow and NIH Pioneer Award). Dr. Baldwin holds a Ph.D. in Immunology from Stanford and performed postdoctoral work in Neurobiology at Columbia University with Dr. Richard Axel. She holds several patents and is a co-founder and board observer of Certego Therapeutics.

Professor Kristin Baldwin
Professor Philip Jordan

Professor Philip Jordan

Dr. Philip Jordan is a professor of Biochemistry & Molecular Biology at Johns Hopkins Bloomberg School of Public Health and a professor at the Uniformed Services University of the Health Sciences. Research in the Jordan laboratory focuses on understanding the molecular mechanisms regulating DNA repair, chromosome segregation and cell cycle progression, processes that are essential for normal organismal development, cellular homeostasis and prevention of diseases. In particular, the Jordan lab studies the aberrant expression and mutation of genes which can result in microcephaly, cognitive and growth retardation, infertility, and predisposition to cancer. His research program uses mouse and human pluripotent stem cells to discover the molecular processes that ensure genome stability during gametogenesis and early development.

Professor Philip Jordan
Dr Sara Vaughn

Dr Sara Vaughn

Dr. Sara Vaughn, MD is an OBGYN and Reproductive Endocrinology and Infertility (REI) Physician in Palo Alto. She has been a practicing physician in reproductive medicine for over 10 years. She is double-board certified in both OBGYN and REI. Her clinical fellowship was completed at Stanford University where she founded a resident-teaching clinic. She was the first medical director of Spring Fertility's Silicon Valley site. Dr. Vaughn frequently consults for mission aligned Silicon Valley Venture Capital funds and early stage ventures who are focused on using innovation and technology to scale high-quality accessible reproductive care.

Dr Sara Vaughn
Professor Mary Herbert

Professor Mary Herbert

Mary Herbert is a Professor of Reproductive Biology at Newcastle University and Scientific Director at Newcastle Fertility Centre. Professor Herbert’s lab advances knowledge of the biology of germ cells and early embryos with the goals of improving understanding of infertility and extending the scope of reproductive technologies to prevent transmission of disease. After seeing how mitochondrial disease was devastating families, Professor Herbert developed a groundbreaking technique to transfer healthy mitochondria to fertilized embryos using nuclear transplantation. This cutting-edge mechanism has the potential to prevent the transmission of fatal mitochondrial disease from mother to child. Professor Herbert’s work has been critical in the development of UK law permitting these new techniques to be offered in clinical treatment. In addition to mitochondrial disease, Mary’s research focuses on the underlying causes of infertility, miscarriage and birth defects in older women. She is a Fellow of the Royal College of Pathologists and a member of the scientific advisory board for the Association of Clinical Embryologists in the UK.

Professor Mary Herbert
Professor Pranam Chatterjee

Professor Pranam Chatterjee

An expert in cellular reprogramming and computational biology trained at MIT and Harvard. He is the upcoming Assistant Professor at Duke University Medical school, academic member of the Global Consortium for Female Reproductive Longevity & Equality (GCRLE) and a current Research Fellow at Harvard Medical School, where he is developing state-of-the-art algorithms and high-throughput experimental screens to interrogate germ cell development for Gameto. Pranam holds a PhD from the MIT Media Lab, where he developed robust CRISPR technologies, utilizing both experimental and computational methodologies. Pranam holds patents on novel Cas9 enzymes, ScCas9, Sc++, and iSpyMac.

Professor Pranam Chatterjee

Bioethics Committee

Alta Charo

Alta Charo

R. Alta Charo, JD (NAM) is Professor Emerita of Law and Bioethics at the University of Wisconsin. She is an internationally renowned leader in the fields of bioethics, biotechnology, and reproductive healthcare policy, and co-chaired the National Academies’ committee on guidelines for embryonic stem cell research. In 2016, as a member of the National Academies' Human Gene Editing Initiative, Alta co-chaired a multidisciplinary committee of experts that examined legal and social implications of gene-editing technologies and made recommendations for national and international governance. She was a member of President Clinton’s Human Embryo Research Panel and National Bioethics Advisory Commission. She also served on President Obama’s transition team, focusing on NIH and FDA, and served as a policy advisor in the Office of the Commissioner at the FDA from 2009-2011. Earlier government service includes positions as a legal and policy analyst at the former congressional Office of Technology Assessment and in the Population Policy division at the US Agency for International Development. In addition to serving on the policy committee for the International Society for Stem Cell research and several other advisory boards relating to stem cell research, she has authored or contributed to over 150 articles, book chapters and government reports on science law and policy.

Alta Charo
Leslie Schrock

Leslie Schrock

Leslie Schrock is an author, entrepreneur, and angel investor working at the convergence of health and technology, primarily in women's and family health. Her first book, Bumpin': The Modern Guide to Pregnancy mixes clinical research with practical advice for working families. Her second book, Fertility Rules, (Simon Element, June 2023) takes the same approach to fertility. Leslie is also an investor in Caribou, Roon, Pangea, Tonal, Perchwell, Cenegenics, Legacy, Kinfield, Neverland, and dbt Labs, advisor to Maven, Alife, Origin, Oath, and Precisely, a member of Gameto’s bioethics board, and on the board of advisors at her alma mater, The University of Texas at Austin. Leslie was named one of Fast Company’s Most Creative People in Business, and has been featured in The Economist, CNBC, Fortune, NPR, Time, GQ, Forbes, Entrepreneur, Wired, and The New York Times.

Leslie Schrock
Andrew Mclaughlin

Andrew Mclaughlin

Andrew McLaughlin is an expert in technology ethics, law, and public policy. He served as Deputy Chief Technology Officer of the United States on President Obama’s senior White House staff and on the Obama/Biden Presidential transition team, as a member of the Technology, Innovation, and Government Reform cluster. He has worked at Google, ICANN, Tumblr, betaworks, Digg, Assembly OSM, Higher Ground Labs, and Code for America. He has also taught at Stanford and Harvard Law Schools and held fellowships at Stanford Law's Center for Internet & Society, Harvard Law School's Berkman Center for Internet and Society, Columbia University's School of International and Public Affairs, the Young Leaders Forum of the National Committee on US-China Relations, the New America Foundation, and Princeton's Center for Information Technology Policy. He has received numerous honors, including being named one of Time Magazine’s Digital Dozen and a Global Leader for Tomorrow by the World Economic Forum.

Andrew Mclaughlin

Join us

If you’re interested in joining our mission-driven team and would like to contribute to our work, please take a look at our open positions or get in touch.

Careers

Our investors help us modernize and improve women's health

Contact us
Future
Insight Partners
Bold
Arcadia
Plumalley
Lux
TAV
Salt
FJ Labs
Overwater Ventures
Anne Wojcicki
Anne Wojcicki
23 and Me
Robert Nelsen
Robert Nelsen
Arch Ventures
Jack Abraham
Jack Abraham
Atomic
Dan Rose
Dan Rose
Coatue Ventures